Not bad terrible numbers, but were expecting a little higher, EBIDTA took a hit due to red sea crisis and Teva requiring workforce.
Business still fundamentally strong and with a pipeline of 70+ new products, depending on how the product launches go and with Teva ramping up a topline of 3000 looks possible. Looking forward to the concall and management tone, generally Mark has always been conservative.
Disc: Not invested but tracking, not a recommendation.
Subscribe To Our Free Newsletter |